CL2023000943A1 - Formas cristalinas de un compuesto farmacéutico. - Google Patents
Formas cristalinas de un compuesto farmacéutico.Info
- Publication number
- CL2023000943A1 CL2023000943A1 CL2023000943A CL2023000943A CL2023000943A1 CL 2023000943 A1 CL2023000943 A1 CL 2023000943A1 CL 2023000943 A CL2023000943 A CL 2023000943A CL 2023000943 A CL2023000943 A CL 2023000943A CL 2023000943 A1 CL2023000943 A1 CL 2023000943A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- crystalline form
- crystalline forms
- pharmaceutical compound
- relates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002305 glucosylceramides Chemical class 0.000 abstract 1
- 150000002339 glycosphingolipids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención hace referencia a una forma cristalina del compuesto (I) y a un método para preparar la forma cristalina del compuesto (I). La invención también provee composiciones farmacéuticas que comprenden la forma cristalina del compuesto (I). Además, la invención hace referencia a métodos para usar esta forma cristalina del compuesto (I) como medicamento y en el tratamiento de una enfermedad que involucra niveles anormales de glucosilceramida y/o niveles elevados de glucoesfingolípidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000943A1 true CL2023000943A1 (es) | 2023-09-29 |
Family
ID=72744696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000943A CL2023000943A1 (es) | 2020-10-02 | 2023-03-30 | Formas cristalinas de un compuesto farmacéutico. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230391724A1 (es) |
| EP (3) | EP3978474A1 (es) |
| JP (2) | JP2023524169A (es) |
| KR (2) | KR102659466B1 (es) |
| CN (1) | CN116390910A (es) |
| AU (2) | AU2021353055B2 (es) |
| BR (2) | BR122022018214A2 (es) |
| CA (1) | CA3193939C (es) |
| CL (1) | CL2023000943A1 (es) |
| DK (1) | DK4114826T3 (es) |
| ES (1) | ES2964105T3 (es) |
| FI (1) | FI4114826T3 (es) |
| IL (1) | IL301882A (es) |
| MA (1) | MA58885B1 (es) |
| MX (1) | MX2023003618A (es) |
| PE (1) | PE20240138A1 (es) |
| TW (1) | TW202229236A (es) |
| WO (1) | WO2022069709A1 (es) |
| ZA (1) | ZA202310184B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| TW202337456A (zh) * | 2022-01-10 | 2023-10-01 | 荷蘭商雅捷法羅斯公司 | Ｇｍ２神經節苷脂症之治療 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3122726T3 (en) | 2014-03-27 | 2018-10-08 | Acad Medisch Ct | N- (5 - ((Aryl or heteroaryl) methyloxy) pentyl) -substituted imino sugars as inhibitors of glucosylceramide synthase |
| EP3314009A2 (en) * | 2015-06-24 | 2018-05-02 | Universiteit Leiden | Glycosylated metabolites |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 TW TW110136766A patent/TW202229236A/zh unknown
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active IP Right Grant
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 IL IL301882A patent/IL301882A/en unknown
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Application Filing
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en active Application Filing
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 US US18/029,842 patent/US20230391724A1/en active Pending
- 2021-10-01 JP JP2022577645A patent/JP2023524169A/ja active Pending
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486A1/en active Pending
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202229236A (zh) | 2022-08-01 |
| PE20240138A1 (es) | 2024-01-30 |
| JP2024054192A (ja) | 2024-04-16 |
| BR122022018214A2 (pt) | 2023-05-09 |
| AU2022291486A1 (en) | 2023-02-02 |
| EP4295847A2 (en) | 2023-12-27 |
| MA58885B1 (fr) | 2023-11-30 |
| BR112022018020B1 (pt) | 2023-12-26 |
| IL301882A (en) | 2023-06-01 |
| MX2023003618A (es) | 2023-07-14 |
| BR112022018020A2 (pt) | 2023-04-18 |
| EP4295847A3 (en) | 2024-02-28 |
| ZA202310184B (en) | 2024-01-31 |
| EP4114826A1 (en) | 2023-01-11 |
| KR20230078798A (ko) | 2023-06-02 |
| ES2964105T3 (es) | 2024-04-04 |
| CA3193939A1 (en) | 2022-04-07 |
| KR102659466B1 (ko) | 2024-04-19 |
| KR20240056628A (ko) | 2024-04-30 |
| DK4114826T3 (da) | 2023-11-13 |
| WO2022069709A1 (en) | 2022-04-07 |
| EP4114826B1 (en) | 2023-08-23 |
| JP2023524169A (ja) | 2023-06-08 |
| AU2021353055B2 (en) | 2022-10-06 |
| NZ798892A (en) | 2023-09-29 |
| CA3193939C (en) | 2024-02-20 |
| EP3978474A1 (en) | 2022-04-06 |
| CN116390910A (zh) | 2023-07-04 |
| FI4114826T3 (fi) | 2023-11-21 |
| AU2021353055A1 (en) | 2022-09-15 |
| US20230391724A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| DOP2023000168A (es) | Compuestos antivirales que contienen nitrilo | |
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| UY39149A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO2024000588A2 (es) | Composiciones y métodos para la inhibición de ras | |
| BR112017018643A2 (pt) | "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas" | |
| BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112017010599A2 (pt) | análogos de ureia ligada substituída como moduladores sirtuin | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CO2022015630A2 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| MX2020004678A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| BR112022001393A2 (pt) | Forma cristalina do inibidor de atr e seu uso | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| CO2023012702A2 (es) | Derivados de diazepina útiles en el tratamiento de clostridium difficile |